The current study aimed to explore the pharmacokinetics of temocillin in patients treated
with haemodialysis and to demonstrated whether or not the pharmacodynamics target of a time
above a MIC of 16 mg/L of more than 40 and 60 % of the dosing interval could be obtained with
a dosing schedule of 1 gram/24 hours, 2 gram/48 hours and 3 gram/72 hours, all of these doses
given after haemodialysis sessions only.
Phase:
Phase 4
Details
Lead Sponsor:
AZ Sint-Jan AV
Collaborators:
Ana Miranda Bastos, Louvain drug research institute, belgium Francoise Van Bambeke, Louvain drug research institute, belgium Paul Tulkens, Louvain drug research institute, belgium